Longeveron Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Marie Washburn hired as CFO/SVP effective July 13, 2026, at $340K base salary plus 45% target bonus and 130K RSUs vesting over 3 years. H.C. Wainwright ATM offering agreement amended June 16, 2026 to narrow FDA representation language. Investor agreement amended May 20, 2026 to clarify investors' 50% proceeds rights if company sells a Rare Pediatric Disease Priority Review Voucher related to its laromestrocel HLHS program, with rights surviving program transfers.
Why this rating
CFO hire routine for $16.5M market-cap biotech; $340K salary is ~2% market cap. Offering/investor amendments are technical clarifications without material cash impact disclosed. No revenue, funding, or clinical data changes.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.